Cerenome, Inc.

Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments.

Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.

HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Health Care Service Corporation (“HCSC”), effective August 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. HCSC represents approximately 27.3 million commercial and Medicare Advantage covered lives and operates Blue Cross and Blue Shield plans in Texas, Illinois, Montana, New Mexico, and Oklahoma and offers Medicare Advantage plans in 30 states and Washington, D.C.